Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04506203
Other study ID # HULaPaz
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 10, 2020
Est. completion date May 31, 2022

Study information

Verified date August 2023
Source Hospital Universitario La Paz
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HYPOTHESIS: During anesthetic pre-oxygenation with high FiO2, pulmonary atelectasis occur, especially in patients < 6 years old, where FRC and pulmonary closing volume may overlap. New borns and children <1 year old are especially vulnerable. OBJECTIVES: 1. Validate "air test" as a individualized and non-invasive diagnostic method of clinically significant atelectasis in pediatrics. 2. Determine what other factors contribute to atelectasis development in pediatrics METHODS: 30 pediatric patients will be studied with ages ranged between 45 postconceptional weeks and16 years old. Baseline SpO2 and lung ultrasound will be performed for each patient upon arrival at the operating theatre before preoxygenation with FiO2 of 1.0 SpO2 will be measured 15 min after intubation during a 5 min long "air test" trial (FiO2 0.25). lung collapse will be verified by lung ultrasound at the end of the 15 min trial. Lung collapse will be eventually granted upon lung US verification by a blind researcher.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date May 31, 2022
Est. primary completion date August 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Weeks to 16 Years
Eligibility Inclusion Criteria: - General anesthesia - Perioperative risk classification (ASA) I, II, III - Newborns (postconceptional age> 45 weeks) to 16 years - Need for oral / nasotracheal intubation Exclusion Criteria: - ASA > III - Basal SpO2 < 97% on air in supine position - Preoperative need for oxygen therapy and / or high-flow nasal cannulas - Expected Difficult airway - Presence of craniofacial disorders that may compromise ventilation - Hemodynamic instability and / or need for inotropics - History of untreated heart disease - Presence or history of pneumothorax - Presence of untreated congenital pulmonary disorders - Refusal to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Air test
Patients will breathe 0.21 < FiO2 < 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.

Locations

Country Name City State
Argentina Hospital Privado de Comunidad Córdoba
Spain Hospital Universitario La Paz Madrid
Spain Hospital Universitario La Princesa Madrid

Sponsors (3)

Lead Sponsor Collaborator
Hospital Universitario La Paz Hospital Privado de Comunidad, Hospital Universitario La Princesa

Countries where clinical trial is conducted

Argentina,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Atelectasis incidence Assess incidence of SpO2 < 97% 15 minutes after anesthesia induction during a 5 minutes long air test (FiO2 < 0.25). 5 minutes
Primary Accuracy of Pediatric Air test trial Assess incidence of lung collapse (hence atelectasis incidence) 15 minutes after anesthesia induction using an air test (FiO2 < 0.25). Collapse blind validation using lung US 5 minutes
Secondary Atelectasis risk factors assessment Determine if there occurs higher atelectasis incidence depending on age, sex, medical records, body weight index or type of surgery 5 minutes
Secondary Atelectasis severity Determine if there is any correlation between SpO2 values during air test and lung collapse, graded upon a validated severity lung collapse image score 5 minutes
See also
  Status Clinical Trial Phase
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Completed NCT04908397 - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension Phase 1
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Completed NCT03682354 - ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Terminated NCT00233207 - IC14 Antibodies to Treat Individuals With Acute Lung Injury Phase 2
Completed NCT00269256 - Stress, Environment, and Genetics in Urban Children With Asthma N/A
Completed NCT00281216 - Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations N/A
Recruiting NCT00129350 - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Phase 1
Active, not recruiting NCT00115297 - Montelukast for Early Life Wheezing Phase 2/Phase 3
Completed NCT00094276 - Intervention for Improving Asthma Care for Minority Children in Head Start N/A
Completed NCT00091767 - Genetic Studies in Difficult to Treat Asthma: TENOR N/A
Completed NCT00083798 - Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland N/A
Completed NCT00233168 - Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents N/A
Completed NCT00069823 - Study of Acid Reflux in Asthma Phase 3